BACKGROUND: The UK Renal Association (RA) and National Institute for Health and Clinical Excellence (NICE) have published clinical practice guidelines which include recommendations for management of anaemia in established renal failure. AIM: To determine the extent to which the guidelines for anaemia management are met in the UK. METHODS: Quarterly data were obtained regarding haemoglobin (Hb) and factors that influence Hb from renal centres in England, Wales, Northern Ireland (EWNI) and the Scottish Renal Registry for the incident and prevalent renal replacement therapy (RRT) cohorts for 2010. RESULTS: In the UK, in 2010 53.6% of patients commenced dialysis therapy with Hb ≥ 10.0 g/dl (median Hb 10.1 g/dl). The median Hb of haemodialysis (HD) patients was 11.5 g/dl with an interquartile range (IQR) of 10.5-12.3 g/dl. Of HD patients 84.6% had Hb ≥ 10.0 g/dl. The median Hb of peritoneal dialysis (PD) patients in the UK was 11.6 g/dl (IQR 10.6-12.5 g/dl). Of UK PD patients, 87.2% had Hb ≥ 10.0 g/dl. The median ferritin in HD patients in EWNI was 444 µg/L (IQR 299-635) and 96% of HD patients had a ferritin ≥ 100 µg/L. The median ferritin in PD patients was 264 µg/L (IQR 148-426) with 86% of PD patients having a ferritin ≥ 100 µg/L. In EWNI the mean Erythropoietin Stimulating Agent (ESA) dose was higher for HD than PD patients (9,020 vs. 6,202 IU/week). CONCLUSIONS: Of prevalent HD patients, 52.7% had Hb ≥ 10 and ≤ 12 g/dl. Of prevalent PD patients, 54.3% had Hb 10.5-12.5 g/dl.
BACKGROUND: The UK Renal Association (RA) and National Institute for Health and Clinical Excellence (NICE) have published clinical practice guidelines which include recommendations for management of anaemia in established renal failure. AIM: To determine the extent to which the guidelines for anaemia management are met in the UK. METHODS: Quarterly data were obtained regarding haemoglobin (Hb) and factors that influence Hb from renal centres in England, Wales, Northern Ireland (EWNI) and the Scottish Renal Registry for the incident and prevalent renal replacement therapy (RRT) cohorts for 2010. RESULTS: In the UK, in 2010 53.6% of patients commenced dialysis therapy with Hb ≥ 10.0 g/dl (median Hb 10.1 g/dl). The median Hb of haemodialysis (HD) patients was 11.5 g/dl with an interquartile range (IQR) of 10.5-12.3 g/dl. Of HDpatients 84.6% had Hb ≥ 10.0 g/dl. The median Hb of peritoneal dialysis (PD) patients in the UK was 11.6 g/dl (IQR 10.6-12.5 g/dl). Of UK PDpatients, 87.2% had Hb ≥ 10.0 g/dl. The median ferritin in HDpatients in EWNI was 444 µg/L (IQR 299-635) and 96% of HDpatients had a ferritin ≥ 100 µg/L. The median ferritin in PDpatients was 264 µg/L (IQR 148-426) with 86% of PDpatients having a ferritin ≥ 100 µg/L. In EWNI the mean Erythropoietin Stimulating Agent (ESA) dose was higher for HD than PDpatients (9,020 vs. 6,202 IU/week). CONCLUSIONS: Of prevalent HDpatients, 52.7% had Hb ≥ 10 and ≤ 12 g/dl. Of prevalent PDpatients, 54.3% had Hb 10.5-12.5 g/dl.
Authors: Ahmad Mitwalli; Abdulkareem Alsuwaida; Jamal Al Wakeel; Saira Usama; Nouf Zainalddain; Mohammed Al Ghonaim; Durdana Hammad Journal: Ann Saudi Med Date: 2013 Sep-Oct Impact factor: 1.526